CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Net Inc. Y/Y Annual
Radnet Inc   (RDNT)
Other Ticker:  
 
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

RDNT's Net Income Growth by Quarter and Year

Radnet Inc 's Net Income results by quarter and year




RDNT Net Income (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - 24.07 6.45 21.14
III Quarter September - 14.56 13.83 8.09
II Quarter June 6.95 -14.28 8.36 13.78
I Quarter March 5.41 4.97 1.31 10.98
FY   12.36 29.32 29.95 53.99



RDNT Net Income second quarter 2024 Y/Y Growth Comment
Radnet Inc in the second quarter 2024 achieved Net Income of $ 6.95 millions compare to net loss recorded in same quarter a year ago.

According to the results reported in the second quarter 2024, Radnet Inc achieved the best Net Income growth in Medical Laboratories industry. While Radnet Inc ' s Net Income no change of % ranks overall at the positon no. in the second quarter 2024.


RDNT Net Income ( Y/Y Growth %) 2024
 2023 2022 2021
IV Quarter December - 273.18 % -69.49 % 106.65 %
III Quarter September - 5.28 % 70.95 % -
II Quarter June - - -39.33 % -
I Quarter March 8.85 % 279.39 % -88.07 % -13.41 %
FY   - -2.1 % -44.53 % -

Financial Statements
Radnet Inc 's second quarter 2024 Net Income $ 6.95 millions RDNT's Income Statement
Radnet Inc 's second quarter 2023 Net Income $ -14.28 millions Quarterly RDNT's Income Statement
New: More RDNT's historic Net Income Growth >>


RDNT Net Income (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
IV Quarter December - 65.32 % -53.36 % 161.31 %
III Quarter September - - 65.43 % -41.29 %
II Quarter June 28.37 % - 538.17 % 25.5 %
I Quarter March -77.52 % -22.95 % -93.8 % 7.33 %
FY (Year on Year)   - -2.1 % -44.53 % -


Compare RDNT Profitability >> Back to RDNT Growth rate Comparisons >>


Net Income second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Radnet Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
1035.49 % 99.79 % -93.79 %
(Dec 31 2012)  


RDNT's II. Quarter Q/Q Net Income Comment
Radnet Inc achieved in the II. Quarter 2024 below company average Net Income jump of 28.37% quarter on quarter, to $ 6.95 millions.

Albeit the II. Quarter 2024 Radnet Inc 's results were lower than the average of 99.79 %, it was still promising sign, as the II. Quarter expension, transcends the % surge in the same quarter a year ago

Within Medical Laboratories industry Radnet Inc achieved highest sequential Net Income growth. While Radnet Inc 's Net Income growth quarter on quarter, overall rank is 506.


Net Income Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #1
Healthcare Sector #30
Overall #506
Net Income Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #1
Healthcare Sector #30
Overall #506
Net Income Q/Q Growth Statistics
High Average Low
1035.49 % 99.79 % -93.79 %
(Dec 31 2012)  


RDNT's II. Quarter Q/Q Net Income Comment
Radnet Inc achieved in the II. Quarter 2024 below company average Net Income jump of 28.37% quarter on quarter, to $ 6.95 millions.

II. Quarter 2024 Radnet Inc 's Net Income Q/Q growth appear to be paradoxical, even if lower than the average increase of 99.79 %, yet it demonstrates real acceleration relative to the % in the II. Quarter 2023.

Within Medical Laboratories industry Radnet Inc achieved highest sequential Net Income growth. While Radnet Inc 's Net Income growth quarter on quarter, overall rank is 506.


Radnet Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)
Cumulative Net Income 12 Months Ending $ 50.98 $ 29.75 $ 29.31 $ 11.69 $ 10.96
Y / Y Net Income Growth (TTM) 365.05 % -11.48 % -2.16 % -73.82 % -71.83 %
Year on Year Net Income Growth Overall Ranking # 55 # 1037 # # 1058 # 2010
Seqeuential Net Income Change (TTM) 71.35 % 1.51 % 150.73 % 6.63 % -67.38 %
Seq. Net Income Growth (TTM) Overall Ranking # 55 # 1037 # # 1058 # 2010

New: More RDNT's historic Net Income Growth >>



Cumulative Net Income growth Comment
Although Radnet Inc 's Annual Net Income growth year on year were below company's average 532.28% , Net Income announced in the Jun 30 2024 period, show improvement in Net Income trend, to cumulative trailing twelve month growth of 365.05% year on year, from -11.48% in Mar 31 2024.

In the Healthcare sector 102 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 55, from total ranking in previous quarter at 1037.

Net Income TTM Q/Q Growth Statistics
High Average Low
16810.84 %
532.28 %
-129.37 %
(Sep 30 2019)  

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 11
Healthcare Sector # 103
Overall # 1538

Net Income TTM Y/Y Growth Statistics
High Average Low
16810.84 %
532.28 %
-129.37 %
(Sep 30 2019)  


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 102
S&P 500 # 1519
Cumulative Net Income growth Comment
Although Radnet Inc 's Annual Net Income growth year on year were below company's average 532.28% , Net Income announced in the Jun 30 2024 period, show improvement in Net Income trend, to cumulative trailing twelve month growth of 365.05% year on year, from -11.48% in Mar 31 2024.

In the Healthcare sector 102 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 55, from total ranking in previous quarter at 1037.

Net Income TTM Q/Q Growth Statistics
High Average Low
16810.84 %
532.28 %
-129.37 %
(Sep 30 2019)  


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 11
Healthcare Sector # 103
Overall # 1538

Net Income TTM Y/Y Growth Statistics
High Average Low
16810.84 %
532.28 %
-129.37 %
(Sep 30 2019)  


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 102
S&P 500 # 1519




Other Net Income Growth
Medical Laboratories Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
RDNT's Net Income Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for RDNT's Competitors
Net Income Growth for Radnet Inc 's Suppliers
Net Income Growth for RDNT's Customers

You may also want to know
RDNT's Annual Growth Rates RDNT's Profitability Ratios RDNT's Asset Turnover Ratio RDNT's Dividend Growth
RDNT's Roe RDNT's Valuation Ratios RDNT's Financial Strength Ratios RDNT's Dividend Payout Ratio
RDNT's Roa RDNT's Inventory Turnover Ratio RDNT's Growth Rates RDNT's Dividend Comparisons



Companies with similar Net Income jump for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Net Income for the quarter ending Jun 30 2024
Biogen Inc -1.63%$ -1.635 millions
Embecta Corp -3.29%$ -3.289 millions
Quest Diagnostics Inc-3.61%$ -3.614 millions
Abbott Laboratories-5.31%$ -5.309 millions
Zoetis Inc -6.87%$ -6.866 millions
Idexx Laboratories Inc-9.34%$ -9.337 millions
Prestige Consumer Healthcare Inc -11.89%$ -11.893 millions
Align Technology inc -13.64%$ -13.639 millions
National Research Corporation-15.10%$ -15.097 millions
Dariohealth Corp -17.94%$ -17.938 millions
Bristol myers Squibb Company-18.92%$ -18.922 millions
Organon and Co -19.42%$ -19.421 millions
U S Physical Therapy Inc-21.21%$ -21.206 millions
Pacira Biosciences inc -26.69%$ -26.693 millions
Privia Health Group Inc -27.00%$ -26.997 millions
West Pharmaceutical Services Inc -28.24%$ -28.240 millions
Neurocrine Biosciences Inc -31.94%$ -31.937 millions
Abbvie Inc -32.26%$ -32.264 millions
Lifevantage Corp-33.62%$ -33.622 millions
Lantheus Holdings Inc -34.06%$ -34.057 millions
Viemed Healthcare Inc -36.61%$ -36.609 millions
Vaso Corporation-44.26%$ -44.257 millions
Nature s Sunshine Products inc -44.42%$ -44.415 millions
Royalty Pharma Plc-44.67%$ -44.675 millions
Globus Medical Inc -44.97%$ -44.968 millions
Amgen Inc -45.90%$ -45.903 millions
Surgery Partners Inc -50.78%$ -50.780 millions
Radnet Inc -52.29%$ -52.294 millions
Option Care Health Inc -53.63%$ -53.635 millions
Pro dex Inc -58.30%$ -58.303 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com